OA12730A - Régime de dosage et composition pharmaceutique pour contraception d'urgence. - Google Patents
Régime de dosage et composition pharmaceutique pour contraception d'urgence. Download PDFInfo
- Publication number
- OA12730A OA12730A OA1200400148A OA1200400148A OA12730A OA 12730 A OA12730 A OA 12730A OA 1200400148 A OA1200400148 A OA 1200400148A OA 1200400148 A OA1200400148 A OA 1200400148A OA 12730 A OA12730 A OA 12730A
- Authority
- OA
- OAPI
- Prior art keywords
- levonorgestrel
- active ingredient
- formulation
- emergency contraception
- additives
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims abstract description 39
- 229960004400 levonorgestrel Drugs 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract 9
- 239000003085 diluting agent Substances 0.000 claims abstract 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 5
- 239000003381 stabilizer Substances 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000013355 food flavoring agent Nutrition 0.000 claims 3
- 235000011194 food seasoning agent Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000003826 tablet Substances 0.000 description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002254 contraceptive effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
- 239000003433 contraceptive agent Substances 0.000 description 5
- 229960002568 ethinylestradiol Drugs 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000002513 anti-ovulatory effect Effects 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940038565 levonorgestrel 1.5 mg Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ORKBYCQJWQBPFG-WOMZHKBXSA-N (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ORKBYCQJWQBPFG-WOMZHKBXSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010052805 Drug tolerance decreased Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- CSUXYWBSYIKFBC-KTTGPIHOSA-N [(6s,8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 CSUXYWBSYIKFBC-KTTGPIHOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000546 inhibition of ovulation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008384 inner phase Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003408 postcoitus contraceptive agent Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0105173A HU227198B1 (en) | 2001-11-27 | 2001-11-27 | Pharmaceutical composition for emergency contraception containing levonorgestrel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12730A true OA12730A (fr) | 2006-06-28 |
Family
ID=89998939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200400148A OA12730A (fr) | 2001-11-27 | 2002-11-26 | Régime de dosage et composition pharmaceutique pour contraception d'urgence. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20050288264A2 (es) |
| EP (1) | EP1448207B1 (es) |
| JP (1) | JP2005516904A (es) |
| KR (1) | KR100908161B1 (es) |
| CN (1) | CN1551774A (es) |
| AP (1) | AP1849A (es) |
| AT (1) | ATE293978T1 (es) |
| AU (1) | AU2002347401A1 (es) |
| BR (1) | BR0210595A (es) |
| CA (1) | CA2450359C (es) |
| DE (1) | DE60203929T2 (es) |
| DK (1) | DK1448207T3 (es) |
| EA (1) | EA006545B1 (es) |
| EC (1) | ECSP045171A (es) |
| ES (1) | ES2239727T3 (es) |
| GE (1) | GEP20063882B (es) |
| HR (1) | HRP20040584B1 (es) |
| HU (1) | HU227198B1 (es) |
| IL (1) | IL159394A0 (es) |
| IS (1) | IS2691B (es) |
| MA (1) | MA27076A1 (es) |
| MX (1) | MXPA04005104A (es) |
| NO (1) | NO333984B1 (es) |
| NZ (1) | NZ530056A (es) |
| OA (1) | OA12730A (es) |
| PL (1) | PL206010B1 (es) |
| PT (1) | PT1448207E (es) |
| RS (1) | RS50768B (es) |
| SI (1) | SI1448207T1 (es) |
| TN (1) | TNSN04048A1 (es) |
| UA (1) | UA79942C2 (es) |
| WO (1) | WO2003045397A1 (es) |
| ZA (1) | ZA200404114B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7867515B2 (en) * | 2006-12-20 | 2011-01-11 | TEVA Woman's Health, Inc. | Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof |
| AU2008341138A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
| US8512745B2 (en) | 2008-12-08 | 2013-08-20 | Laboratoire Hra Pharma | Ulipristal acetate tablets |
| WO2010066883A1 (en) * | 2008-12-12 | 2010-06-17 | Laboratoire Hra-Pharma | A method for contraception |
| EP3106167A1 (en) | 2009-04-14 | 2016-12-21 | Laboratoire HRA Pharma | Method for on-demand contraception |
| KR20120044307A (ko) * | 2009-06-23 | 2012-05-07 | 바이엘 파마 악티엔게젤샤프트 | 긴급 피임용 제약 조성물 |
| CN101732324B (zh) * | 2009-12-31 | 2011-12-07 | 广州朗圣药业有限公司 | 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法 |
| KR101994805B1 (ko) | 2011-06-01 | 2019-07-01 | 에스테트라 에스.피.알.엘. | 에스테트롤 중간체의 제조 방법 |
| CN103619867B (zh) | 2011-06-01 | 2015-12-23 | 埃斯特拉公司 | 用于产生雌四醇中间体的方法 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| DK2741824T3 (en) * | 2011-08-11 | 2017-07-10 | Estetra Sprl | Use of estetrol as emergency contraception |
| MX2015006499A (es) | 2012-11-22 | 2015-08-14 | Bayer Pharma AG | Uso y regimen de aplicacion de una composicion farmaceutica que comprende levonorgestrel y un inhibidor de la cox para la anticocepcion "a la carta". |
| WO2014187744A1 (de) | 2013-05-23 | 2014-11-27 | Bayer Pharma Aktiengesellschaft | Pharmazeutische zusammensetzung und deren verwendung sowie anwendungsregime dieser pharmazeutischen zusammensetzung zur bedarfsweisen („on-demand") kontrazeption |
| CN103877058A (zh) * | 2014-03-26 | 2014-06-25 | 邵娜 | 一种左炔诺孕酮片及其制备工艺 |
| NO3106148T3 (es) | 2015-06-18 | 2018-08-11 | ||
| MD3310346T2 (ro) | 2015-06-18 | 2021-06-30 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| EP3701944B1 (en) | 2015-06-18 | 2021-12-08 | Estetra SRL | Orodispersible dosage unit containing an estetrol component |
| MD3310345T2 (ro) | 2015-06-18 | 2021-07-31 | Estetra Sprl | Comprimată orodispersabilă ce conține estetrol |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN110917154A (zh) * | 2019-12-12 | 2020-03-27 | 上海信谊天平药业有限公司 | 一种左炔诺孕酮片的制备方法 |
| WO2022026901A2 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk antagonists for contraception |
-
2001
- 2001-11-27 HU HU0105173A patent/HU227198B1/hu unknown
-
2002
- 2002-11-26 WO PCT/HU2002/000129 patent/WO2003045397A1/en active IP Right Grant
- 2002-11-26 RS YUP-42/04A patent/RS50768B/sr unknown
- 2002-11-26 GE GE5567A patent/GEP20063882B/en unknown
- 2002-11-26 PL PL369520A patent/PL206010B1/pl unknown
- 2002-11-26 NZ NZ530056A patent/NZ530056A/en not_active IP Right Cessation
- 2002-11-26 AP APAP/P/2004/003046A patent/AP1849A/en active
- 2002-11-26 EA EA200400731A patent/EA006545B1/ru unknown
- 2002-11-26 SI SI200230132T patent/SI1448207T1/xx unknown
- 2002-11-26 DE DE60203929T patent/DE60203929T2/de not_active Expired - Lifetime
- 2002-11-26 CA CA2450359A patent/CA2450359C/en not_active Expired - Lifetime
- 2002-11-26 AU AU2002347401A patent/AU2002347401A1/en not_active Abandoned
- 2002-11-26 CN CNA028137523A patent/CN1551774A/zh active Pending
- 2002-11-26 EP EP02783334A patent/EP1448207B1/en not_active Expired - Lifetime
- 2002-11-26 AT AT02783334T patent/ATE293978T1/de active
- 2002-11-26 PT PT02783334T patent/PT1448207E/pt unknown
- 2002-11-26 ES ES02783334T patent/ES2239727T3/es not_active Expired - Lifetime
- 2002-11-26 JP JP2003546899A patent/JP2005516904A/ja not_active Withdrawn
- 2002-11-26 IL IL15939402A patent/IL159394A0/xx unknown
- 2002-11-26 BR BR0210595-0A patent/BR0210595A/pt not_active Application Discontinuation
- 2002-11-26 MX MXPA04005104A patent/MXPA04005104A/es active IP Right Grant
- 2002-11-26 KR KR1020047002069A patent/KR100908161B1/ko active IP Right Grant
- 2002-11-26 DK DK02783334T patent/DK1448207T3/da active
- 2002-11-26 OA OA1200400148A patent/OA12730A/fr unknown
- 2002-11-26 UA UA20040504015A patent/UA79942C2/uk unknown
-
2003
- 2003-12-05 IS IS7065A patent/IS2691B/is unknown
-
2004
- 2004-03-26 TN TNP2004000048A patent/TNSN04048A1/en unknown
- 2004-04-20 NO NO20041607A patent/NO333984B1/no not_active IP Right Cessation
- 2004-04-21 MA MA27643A patent/MA27076A1/fr unknown
- 2004-05-26 ZA ZA2004/04114A patent/ZA200404114B/en unknown
- 2004-06-24 HR HR20040584 patent/HRP20040584B1/xx not_active IP Right Cessation
- 2004-06-25 EC EC2004005171A patent/ECSP045171A/es unknown
- 2004-10-05 US US10/495,923 patent/US20050288264A2/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12730A (fr) | Régime de dosage et composition pharmaceutique pour contraception d'urgence. | |
| JP5801801B2 (ja) | 緊急避妊のための医薬組成物及び処置方法 | |
| HU208487B (en) | Process for producing composition for inhibiting human ovulation and for preventinvg mammal cancer | |
| KR20130048227A (ko) | 드로스피레논을 포함하는 약학적 조성물 및 피임용 키트 | |
| MX2008014941A (es) | Metodos para administrar formas de dosificacion solida de etinil estradiol y profarmacos del mismo con biodisponibilidad mejorada. | |
| JP2002509524A (ja) | エストロゲン化合物とプロゲステロン様化合物よりなるホルモン組成物 | |
| EP0177654B1 (fr) | Association synergique contraceptive | |
| CA2388857C (fr) | Medicament contraceptif a base d'un progestatif et d'un oestrogene et son mode de preparation | |
| WO2011069871A1 (en) | A method for providing emergency contraception using ulipristal acetate | |
| TW201420103A (zh) | 包含左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及ｃｏｘ抑制劑之醫藥組合物於「依需求（ｏｎ ｄｅｍａｎｄ）」避孕之用途及應用療法 | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| KR20240040774A (ko) | 프로게스토겐만을 이용한 경구 피임법 | |
| Visser et al. | Hormones and hormone antagonists | |
| FR2886151A1 (fr) | Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose | |
| GB2310600A (en) | Pharmaceutical composition containing gestrinone and use thereof |